{
  "id": 10969581,
  "title": "CAR-T Therapy Shows Durable Benefits in Myasthenia Gravis",
  "url": "https://urgent.news/2026/09/30/car-t-therapy-shows-durable-benefits-in-myasthenia-gravis",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-30T14:47:30.000Z",
  "source": {
    "name": "MedPage Today",
    "slug": "medpage-today",
    "url": "https://www.medpagetoday.com/meetingcoverage/aanem/123195"
  },
  "original_language": "en",
  "account": null,
  "summary": "(MedPage Today) -- Mivocabtagene autoleucel (miv-cel), an autologous CD19 chimeric antigen receptor (CAR)-T cell therapy, showed benefits lasting 6 months or longer for generalized myasthenia gravis patients in the phase II portion of the KYSA...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}